← Leaderboards
William Jay Simpson
Cerrx, Inc.
$1,312,055
Attributed
$1,312,055
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $648K · FY2014–18$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,312,055 · 1
By mechanism
R44$1,312,055 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Animals”
- David Heimbrook · Leidos Biomedical Research, Inc.$534,904,829
- Richard Webby · St. Jude Children'S Research Hospital$259,408,394
- Eric S Lander · Whitehead Institute For Biomedical Res$209,574,154
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Richard K. Wilson · Washington University$130,501,539
- Mark S Klempner · Tufts Medical Center$129,182,794
Research focus
AnimalsAntineoplastic AgentsBaseBehaviorBiochemicalBiochemistryBloodBolus InfusionBurden Of IllnessCalibrationCancer CellCancer Cell LineCancer TherapyCanis FamiliarisCellsCeramidesChildhoodCisplatinClinical TrialsClinical Trials DesignContinuous InfusionCostCytotoxicAdult
Grant awards (3)
A Phase I trial combining IV fenretinide and IV safingol to target overproduction$473,425
R44 · FY2018 · CA · contact PI
A Phase I trial combining IV fenretinide and IV safingol to target overproduction$648,029
R44 · FY2017 · CA · contact PI
A Phase I trial combining IV fenretinide and IV safingol to target overproduction$190,601
R44 · FY2014 · CA · contact PI